Trial · NCT00577135
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Patient Well Being, as Determined by a Visual Analog Scale | Measured at 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| PRIMARY | Change in Serum Creatinine | Measured at baseline and 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Weight | baseline and 96 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | lbs | MEAN |
| SECONDARY | Proportion of Patients Free of Congestion | Measured at 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | percentage of participants | NUMBER |
| SECONDARY | Dyspnea, as Determined by Visual Analog Scales | Measured at 24 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| SECONDARY | Change in Serum Creatinine | baseline and 24 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Cystatin C | baseline and 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/L | MEAN |
| SECONDARY | Change in Serum Creatinine | baseline and 48 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Serum Creatinine | baseline and 96 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Serum Creatinine | baseline and day 7 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Serum Creatinine | baseline and day 60 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Patient Well Being, as Determined by a Visual Analog Scale | Measured at 24 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| SECONDARY | Patient Well Being, as Determined by a Visual Analog Scale | 48 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| SECONDARY | Dyspnea VAS | 48 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| SECONDARY | Dyspnea VAS | 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | units on a scale | MEAN |
| SECONDARY | Change in Cystatin C | baseline and day 7 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/L | MEAN |
| SECONDARY | Change in Cystatin C | baseline and day 60 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/L | MEAN |
| SECONDARY | Change in Uric Acid | baseline and 72 hours | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Uric Acid | baseline and day 7 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
| SECONDARY | Change in Uric Acid | baseline and Day 60 | Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis. | mg/dL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00577135/outcomes